Health and wellness products company USANA Health Sciences (NYSE:USNA) will be announcing earnings results tomorrow after market close. Here's what you need to know.
Last quarter USANA reported revenues of $213.4 million, down 8.5% year on year, missing analyst expectations by 3.2%. It was a weak quarter for the company, with a miss of analysts' revenue estimates and full-year revenue guidance missing analysts' expectations.
Is USANA buy or sell heading into the earnings? Find out by reading the original article on StockStory.
This quarter analysts are expecting USANA's revenue to decline 6.8% year on year to $212.4 million, improvement on the 14.7% year-over-year decrease in revenue the company had recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.52 per share.
Majority of analysts covering the company have reconfirmed their estimates over the last thirty days, suggesting they are expecting the business to stay the course heading into the earnings. The company missed Wall St's revenue estimates four times over the last two years.
Looking at USANA's peers in the consumer staples segment, some of them have already reported Q4 earnings results, giving us a hint of what we can expect. Post delivered top-line growth of 25.5% year on year, beating analyst estimates by 2.4% and Lamb Weston reported revenues up 35.7% year on year, exceeding estimates by 1.9%. Post traded up 4.8% on the results, and Lamb Weston was down 1.4%.
Read the full analysis of Post's and Lamb Weston's results on StockStory.
Investors in the consumer staples segment have had steady hands going into the earnings, with the stocks down on average 0.4% over the last month. USANA is down 7.4% during the same time, and is heading into the earnings with analyst price target of $68, compared to share price of $47.2.
The author has no position in any of the stocks mentioned.
